EMA Peptide Biosimilar Regulatory Pathway Updates: What Developers Need to Know in 2026

The European Medicines Agency's (EMA) biosimilar regulatory framework is the most mature in the world for follow-on biological products, and its application to peptide therapeutics, including both synthetic peptide analogs that fall within the biological product framework and complex peptides that occupy a regulatory borderline between chemical synthesis and biological manufacturing, continues to evolve in 2026. Understanding the current EMA position is essential for companies developing follow-on peptide products for the European market.

EMA Biosimilar Framework: Applicability to Peptides

The EMA regulates follow-on versions of approved biological medicines as biosimilars, requiring demonstration of biosimilarity (similar quality, safety, and efficacy) rather than just bioequivalence as required for generic small-molecule drugs. The biosimilar pathway applies when the reference product is classified as a biological medicine.

For peptide products, the regulatory classification question is the critical first step: is the product a biological medicine (subject to biosimilar requirements) or a well-characterized chemical entity (subject to generic requirements)?

The EMA's general guidance is:

• Peptides produced by SPPS or solution-phase chemical synthesis, with molecular weights below approximately 1,000-1,500 Da, are typically regulated as chemical substances (generic pathway)
• Longer synthetic peptides (above ~40 amino acids) and peptides produced by recombinant biological processes are typically regulated as biological medicines (biosimilar pathway)
• Peptides in the intermediate molecular weight range (1,000-6,000 Da) may be regulated under either pathway depending on their structural complexity, manufacturing method, and the nature of their reference product

The ambiguity at the classification boundary creates regulatory uncertainty that can significantly affect development costs, timelines, and data requirements. Early scientific advice from EMA is strongly recommended for peptide developers planning European market entry, to align on the applicable regulatory pathway before committing development resources.

2026 Updates to EMA Biosimilar Guidelines

The EMA's 2025-2026 update cycle for biosimilar product class guidelines included several revisions with direct relevance to peptide biosimilar development:

Analytical comparability requirements for complex peptides. The updated EMA guidelines have increased the analytical characterization requirements for biosimilar peptides that have structural complexity beyond a simple linear amino acid sequence. For peptides with disulfide bonds, PEGylation, acylation, or other post-synthetic modifications, the analytical comparison package required for biosimilar approval now includes specific requirements for:

• Multi-dimensional mass spectrometry confirming identical amino acid sequence and modification site
• Higher-order structure characterization by CD spectroscopy, NMR, or other applicable methods, with justification of why any structural differences observed are not clinically meaningful
• Aggregation characterization by DLS, AUC, and size exclusion chromatography with comparison to the reference product across multiple lots

These enhanced analytical requirements reflect the EMA's recognition that for structurally complex peptides, analytical similarity must be demonstrated at a deeper structural level than HPLC purity and potency testing alone.

Clinical trial requirements for GLP-1 analog biosimilars. As the first GLP-1 receptor agonists approach European patent expiry and biosimilar development programs progress, the EMA has provided specific guidance on the clinical data package required for GLP-1 biosimilar approval. Key points:

• Pharmacokinetic and pharmacodynamic comparative studies are required, with specific endpoints including plasma glucose-lowering response and GLP-1 receptor-mediated GI tolerability assessment
• Immunogenicity comparative assessment requires anti-drug antibody (ADA) testing with validated, peptide-specific assays capable of detecting both binding and neutralizing antibodies
• The reference product for European biosimilar applications must be the EU-approved reference product (not a US or other market-approved version), requiring that EU reference product comparator studies be conducted

Interchangeability provisions. The EMA does not have a formal "interchangeable" designation analogous to the FDA's interchangeability pathway for biosimilars, but automatic substitution at the pharmacy level is governed by national competent authority rules in each EU member state. The practical implication for peptide biosimilar sponsors is that the commercial success of a biosimilar product in the EU depends on individual member state substitution policies, which vary considerably: automatic substitution is permitted in some member states and restricted in others.

Scientific Advice Process for Peptide Biosimilar Development

The EMA's scientific advice procedure is the primary mechanism for prospectively aligning on the development requirements for a peptide biosimilar program before the significant investment in the biosimilar package is committed. Key scientific advice topics for peptide biosimilar developers include:

Reference product selection. Confirming the EU reference product for the comparability exercise, and any scientific justification for using data generated against non-EU reference products (extrapolation is possible but must be scientifically justified).

Analytical similarity package scope. Pre-aligning on the analytical methods, comparisons, and acceptance criteria that will be required for the comparability assessment. For complex peptides, EMA scientific advice can prevent costly analytical development work that does not align with regulatory expectations.

Clinical data requirements. Discussing whether a "totality of evidence" approach that minimizes clinical requirements is supportable for the specific product based on analytical comparability and mechanistic understanding, or whether head-to-head comparative clinical studies are required.

Extrapolation of indications. When the reference product is approved in multiple indications, discussing whether biosimilarity demonstrated in one indication can support approval in all reference product indications without separate clinical studies.

Implications for Japanese and Global Regulatory Harmonization

The EMA's approach to peptide biosimilars is increasingly influential on the Japanese PMDA and emerging market regulatory frameworks, which are moving toward the ICH-harmonized approach. Developers targeting global regulatory submissions should assess the extent to which an EMA-compliant development package supports simultaneous or sequential filings in Japan, Canada, and other ICH-aligned markets.

The FDA has taken a somewhat different approach to the categorization of complex peptides, classified more synthetic peptides as 505(b)(2) NDA eligible rather than biosimilar pathway eligible, creating strategic decisions for global biosimilar developers about which regulatory framework to pursue in the US market.

For companies pursuing global follow-on peptide development strategies, the regulatory landscape in 2026 rewards early scientific advice engagement across all major markets, strategic integration of analytical comparability platforms that can address both EMA and FDA requirements, and regulatory affairs expertise that spans both the biosimilar and 505(b)(2) pathways.

The EMA biosimilar pathway, with its rigorous analytical and clinical requirements, has produced a high-quality cohort of approved peptide biosimilars that have delivered meaningful cost savings to European healthcare systems while maintaining therapeutic quality, a track record that supports continued investment in the European follow-on peptide market.